-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2024-511437-35-00
10
2026-01-05
Patients aged 18-65 years old with newly diagnosed previously untreate
-
2024-518465-10-00
4
2025-12-12
Multiple Autoimmune Glomerular Diseases
-
2025-521358-41-00
4
2025-12-11
CLDN18.2 positive gastro-esophageal adenocarcinoma
-
2024-513586-39-00
5
2025-12-10
Prostate Cancer
-
2024-519493-39-00
5
2025-12-09
High-risk Non-muscle-invasive Bladder
Cancer with Susceptible FGFR Alt
-
2024-519712-13-00
5
2025-12-08
Hypertriglyceridemia (HTG)
-
2025-521242-26-00
4
2025-11-27
Moderately to Severely Active Ulcerative Colitis
-
2025-521511-40-00
10
2025-11-18
metastatic non-small cell lung cancer
-
2024-519917-72-00
5
2025-10-29
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2024-514693-47-01
11
2025-10-28
EGFR mutated locally advanced or metastatic non-small cell lung cancer
-
2024-518365-10-00
5
2025-10-28
Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
-
2024-517184-23-00
4
2025-10-16
platinum-resistant advanced high-grade epithelial ovarian, primary per
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2024-514822-21-00
5
2025-10-02
Platinum-resistant Ovarian Cancer
-
2024-517780-24-00
5
2025-09-18
Lung Cancer
-
2024-518586-10-00
10
2025-09-18
Non-Squamous Non-Small Cell Lung Cancer
-
2024-517051-12-00
4
2025-09-16
Relapsed primary large B-cel lymphoma of the central nervous system
-
2025-520672-26-00
9
2025-09-16
Gastrointestinal Neoplasms
-
2024-518154-16-00
5
2025-08-27
non-small cell lung cancer
-
2024-520154-38-00
5
2025-07-29
Acute Myeloid Luekemia
-
2024-515884-69-00
5
2025-07-16
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
-
2024-517247-31-00
5
2025-07-07
Newly Diagnosed Higher Risk Myelodysplastic Syndrome
-
2024-513682-40-01
5
2025-07-04
Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer